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A B S T R A C T
The BDProbeTec MTB assay for direct detection
of Mycobacterium tuberculosis was evaluated in
comparison with the AMTD-II assay on 94 sam-
ples from different patients with clinical suspicion
of tuberculosis. Using a combination of culture on
Lowenstein–Jensen medium (with or without
preculture in BACTEC 9000) and clinical diagno-
sis as the standard, BDProbeTec MTB showed
high sensitivity and specificity (96.1% and 100%,
respectively), similar to AMTD-II (96.1% and
97.1%, respectively), with significantly higher
sensitivity than the Ziehl–Neelsen stain for acid-
fast bacilli (73%, p < 0.05).
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Tuberculosis (TB) remains a global health prob-
lem, with one-third of the world’s population
infected with Mycobacterium tuberculosis [1]. Iden-
tification of infected patients is still based on
staining smears for acid-fast bacilli (AFB) and
culturing for mycobacteria, but staining is neither
sensitive (40–70% sensitivity in patients with
pulmonary TB) nor specific for M. tuberculosis
[2,3]. Mycobacterial culture combined with bio-
chemical identification provides a specific diag-
nosis, but requires ‡ 2–3 weeks [2,3].
In response to the need for a more rapid
diagnostic test for TB, various nucleic acid ampli-
fication tests have been developed for direct
detection of the M. tuberculosis complex in respir-
atory specimens [4–11]. Among these, the Ampli-
fied Mycobacterium Tuberculosis Direct test
(AMTD; Gen-Probe, San Diego, CA, USA), based
on transcription-mediated amplification of
M. tuberculosis-specific 16S rRNA sequences, was
the first molecular assay to be approved by the
USA Food and Drug Administration for direct
detection of M. tuberculosis in respiratory speci-
mens [6,8–10]. More recently, the BDProbeTec
MTB assay (Becton Dickinson, Sparks, MD, USA),
a semi-automated system based on thermophilic
strand displacement amplification [12,13], has
been developed. The amplification target is the
internal region of IS6110, an insertion sequence
that exists in multiple copies in the genome of the
M. tuberculosis complex [14,15]. Both assays have
elevated sensitivity (> 90%) and specificity
(> 99%) [6,8–10,16–18].
This study evaluated the performance of
BDProbeTec MTB for the molecular diagnosis of
TB in comparison with AMTD-II, the standard
AFB-smear, and bacterial culture on Lowenstein-
Jensen solid medium and in BACTEC MYCO ⁄
F-Sputa liquid medium (Becton Dickinson). In
total, 94 consecutive clinical specimens (69 sputa,
13 urines, five cerebrospinal fluids and seven other
extrapulmonary specimens), all from different
patients with a high TB suspicion, were collected
from January 2000 through September 2001 and
submitted to the Clinical Pathology Laboratory,
National Institute for Infectious Diseases IRCCS ‘L.
Spallanzani’, Rome, Italy, for detection of myco-
bacteria. Samples from patients with a previous
diagnosis of TB or who were undergoing anti-TB
chemotherapy were excluded from the study.
Specimens were liquefied with Sputasol
(Oxoid, Basingstoke, UK), concentrated by cen-
trifugation (3000 g for 20 min), and decontamin-
ated with Mycoprep (Becton Dickinson). The
sediment (c. 50 lL) was used to prepare a smear
for Ziehl–Neelsen staining [2]. Phosphate-
buffered saline was added to decontaminated
sediment to give a volume of 2 mL. For culture,
0.5 mL of the suspension was inoculated into a
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40-mL bottle of BACTEC MYCO ⁄F-Sputa liquid
medium containing the PANTA ⁄F antimicrobial
mixture and SUPPLEMENT ⁄ F (Becton Dickin-
son). Also, two 0.1-mL aliquots were inoculated
into duplicate Lowenstein–Jensen tubes. The
remainder was stored at ) 20 C for batch testing
by BDProbeTec MTB and AMTD-II. BACTEC
bottles were incubated at 37 C and monitored
for 40 days in a BACTEC 9000 MB fluorometric
instrument. BACTEC-positive cultures were cul-
tured on to Lowenstein–Jensen medium before
bacterial identification. Lowenstein–Jensen tubes
were incubated at 37 C and examined weekly for
8 weeks. Specimens that yielded M. tuberculosis
growth on Lowenstein–Jensen medium, either
directly or after growth in BACTEC 9000 MB,
were considered as culture-positive. Mycobacte-
rial isolates were identified by conventional bio-
chemical tests [2] and the Accuprobe system
(Gen-Probe). The BDProbeTec MTB and AMTD-
II tests were performed as recommended by the
manufacturers. Positive and negative amplifica-
tion controls were included in each AMTD-II run
[6,8,9,12,13,16–18]. Preliminary assessment of
both nucleic acid amplification-based assays indi-
cated a lower detection limit of ‡ 20 M. tuberculo-
sis ATCC 25177 cells ⁄mL.
Of the 94 clinical samples from suspected TB
patients, 25 yielded M. tuberculosis cultures
(Table 1); these comprised 21 sputa, one urine, one
cerebrospinal fluid and two extrapulmonary spec-
imens. No mycobacteria other than M. tuberculosis
were found. Of the 25 M. tuberculosis culture-posit-
ive samples, 19 (76%) were also AFB-smear posit-
ive, while two (3%) of the 69 culture-negative
samples were AFB-smear positive (Table 1). Con-
sidering M. tuberculosis culture as the standard for
laboratory diagnosis of TB, both molecular tests
detected 24 of 25 M. tuberculosis culture-positive
samples (96% sensitivity for both tests; p < 0.05
compared with AFB-smear; Table 1). Similarly, the
BDProbeTec MTB and AMTD-II assays had high
specificity, yielding positive results for only one
(1.4%) and three (4.3%) of 69 M. tuberculosis cul-
ture-negative samples, respectively.
Concordance analysis indicated that the per-
formances of the BDProbeTec MTB and AMTD-
II systems were similar to the standard culture
assay (p > 0.10; McNemar test, all comparisons).
Comparatively, the two amplification assays
were similar (p > 0.10; McNemar test), and only
five of the 94 samples tested gave discordant
results between culture and molecular tests. Two
of these samples (one sputum and one abscess
fluid), for which only the AMTD-II assay yielded
positive results, were probably false-positives
since other samples from the same patient on
different days were negative by all tests, and no
clinical evidence of TB was observed during a
1-year follow-up. One culture-negative urine
sample was positive by both BDProbeTec MTB
and AMTD-II tests, but additional urine samples
collected subsequently from the same patient
were also culture-positive for M. tuberculosis. A
low M. tuberculosis concentration in this sample
might have hampered culture initially, and this
result was redesignated as a culture false-negat-
ive. Two false-negative results were also ob-
tained in the molecular tests, of which the first
was a M. tuberculosis culture-positive sputum
sample that was also positive only by AMTD-
II. The second was a cerebrospinal fluid that was
also positive only by BDProbeTec MTB test,
raising the possibility that the presence of RNase
in this sample may have prevented template
amplification by AMTD-II [19]. Notably, the
AFB-smear was positive for this last sample.
Overall, the clinical performances of the
BDProbeTec MTB and AMTD-II assays appeared
to be similar in terms of both sensitivity (96.1%
for both tests) and specificity (100% for the former
and 97.1% for the latter). Positive and negative
predictive values for AMTD-II were 92.6% and
98.5%, with corresponding values for BDProbe-
Table 1. Results of the AFB-smear,
AMTD-II and BDProbeTEC MTB in
Mycobacterium tuberculosis culture-
positive and -negative samplesa
Number of
samples
Number of positive samplesa
AFB-stain AMTD-II BDProbetec MTB
M. tuberculosis
culture-positive
25 19 (76%) 24 (96%)b 24 (96%)b
M. tuberculosis
culture-negative
69 2 (3%) 3 (4%) 1 (1%)
aResults are presented as frequencies and percentages. Frequencies were compared by v2 test; concordance between
tests was analysed by McNemar’s test.
bp < 0.05 in comparison with AFB-stain.
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Tec MTB of 100% and 98.6%, respectively. In the
context of this comparative evaluation, it should
be highlighted that BDProbeTec MTB offers some
technical advantages at the level of automation,
internal quality control, sample containment and
laboratory safety [6,8,9,12,13,16–18].
In conclusion, the data suggest that the
BDProbeTec MTB test is a sensitive and specific
tool for direct detection of M. tuberculosis in a
variety of clinical specimens, including cerebro-
spinal fluid or urine. However, given the paucity
of non-respiratory specimens included in this
study, additional testing of such specimens is
indicated.
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